Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing China-only randomised study conducted by its partner TJ Biopharma ...
A second asset is AB680 (quemliclustat), a small molecule CD73 antibody running a phase 3 trial in pancreatic cancer. There’s a third molecule, Etrumadenant, and two more, Casdatifan and ...